Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily antibiotic stop a deadly hospital infection?

NCT ID NCT07221370

Prevention Sponsor: Riverside University Health System Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a daily dose of oral vancomycin can prevent Clostridioides difficile (C. diff) infection in critically ill adults who are already on other antibiotics in the hospital. About 176 high-risk patients will receive either vancomycin or a placebo while they are in the hospital and for a short time after. Researchers will track who develops C. diff and also watch for any rise in antibiotic-resistant bacteria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vancomycin (an antibiotic taken by mouth)
What this could lead to
If it works, this could give doctors a simple way to prevent dangerous C. diff infections in high-risk hospital patients, reducing illness and deaths.
What could go wrong
This is a mid-stage trial with only 176 participants, so results may not apply to all patients. There is also a risk that using vancomycin could increase antibiotic-resistant bacteria like VRE.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 176 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Must meet all 3 criteria: * Adults aged 18 years and older. * Receiving ≥ 72 hours of a systemic antibiotic during index hospitalization. * Admitted ≥ 72 hours into their index hospitalization. 2. And must meet 2 additional of the following high-risk criteria * Age ≥ 65 years * Previous residence in long-term care facility * Previous proton pump inhibitor use (chronic or as needed) * Inflammatory bowel disease * Immunocompromised state (HIV/AIDS; transplant recipient; receipt of prednisone 20 mg daily for at least one month, immunosuppressants, or chemotherapy) * End stage renal disease (ESRD) * Diabetes mellitus * Receipt of catecholamines (norepinephrine at a rate of ≥ 5 mcg/min) * Hospitalized ≤ 30 days prior to the index hospitalization. * Received systemic antibiotics during that prior hospitalization. Exclusion Criteria: * Pregnant or breastfeeding women * Currently incarcerated individuals * Individual or legal representative whose informed consent cannot be obtained * Subject not expected to survive the ICU stay or subject likely to be considered for palliative or hospice care * Receiving concurrent treatment with metronidazole for any indication * One-time empiric use of metronidazole is allowed and does not constitute an exclusion criterion * Receiving concurrent probiotics * Allergic reaction or had a contraindication for use of enteral vancomycin * History of prior CDI within the past 90 days of randomization * Had suspected active CDI prior to inclusion * Infection requiring more than 14 21 days of systemic antibiotics during index hospitalization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clostridium difficile infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Clostridium infectious disease Enterococcus infectious disease Clostridium difficile colitis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clostridium difficile infection Vancomycin resistant enterococci infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Riverside University Health System

    RECRUITING

    Moreno Valley, California, 92373, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.